127 related articles for article (PubMed ID: 32586358)
1. Prognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanoma.
Hoffmann F; Zarbl R; Niebel D; Sirokay J; Fröhlich A; Posch C; Holderried TAW; Brossart P; Saavedra G; Kuster P; Strieth S; Gielen GH; Ring SS; Dietrich J; Pietsch T; Flatz L; Kristiansen G; Landsberg J; Dietrich D
Clin Epigenetics; 2020 Jun; 12(1):94. PubMed ID: 32586358
[TBL] [Abstract][Full Text] [Related]
2.
Klümper N; Ralser DJ; Zarbl R; Schlack K; Schrader AJ; Rehlinghaus M; Hoffmann MJ; Niegisch G; Uhlig A; Trojan L; Steinestel J; Steinestel K; Wirtz RM; Sikic D; Eckstein M; Kristiansen G; Toma M; Hölzel M; Ritter M; Strieth S; Ellinger J; Dietrich D
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34446578
[TBL] [Abstract][Full Text] [Related]
3. PD-1 (PDCD1) Promoter Methylation Is a Prognostic Factor in Patients With Diffuse Lower-Grade Gliomas Harboring Isocitrate Dehydrogenase (IDH) Mutations.
Röver LK; Gevensleben H; Dietrich J; Bootz F; Landsberg J; Goltz D; Dietrich D
EBioMedicine; 2018 Feb; 28():97-104. PubMed ID: 29396294
[TBL] [Abstract][Full Text] [Related]
4. Variable indoleamine 2,3-dioxygenase expression in acral/mucosal melanoma and its possible link to immunotherapy.
Iga N; Otsuka A; Hirata M; Kataoka TR; Irie H; Nakashima C; Matsushita S; Uchi H; Yamamoto Y; Funakoshi T; Fujisawa Y; Yoshino K; Fujimura T; Hata H; Ishida Y; Kabashima K
Cancer Sci; 2019 Nov; 110(11):3434-3441. PubMed ID: 31509303
[TBL] [Abstract][Full Text] [Related]
5.
Klümper N; Wüst L; Saal J; Ralser DJ; Zarbl R; Jarczyk J; Breyer J; Sikic D; Wullich B; Bolenz C; Roghmann F; Hölzel M; Ritter M; Strieth S; Hartmann A; Erben P; Wirtz RM; Landsberg J; Dietrich D; Eckstein M
Oncoimmunology; 2023; 12(1):2267744. PubMed ID: 37868689
[TBL] [Abstract][Full Text] [Related]
6. Molecular and immune correlates of TIM-3 (HAVCR2) and galectin 9 (LGALS9) mRNA expression and DNA methylation in melanoma.
Holderried TAW; de Vos L; Bawden EG; Vogt TJ; Dietrich J; Zarbl R; Bootz F; Kristiansen G; Brossart P; Landsberg J; Dietrich D
Clin Epigenetics; 2019 Nov; 11(1):161. PubMed ID: 31747929
[TBL] [Abstract][Full Text] [Related]
7. Soluble Immune Checkpoint Molecules as Predictors of Efficacy in Immuno-Oncology Combination Therapy in Advanced Renal Cell Carcinoma.
Ueda K; Uemura K; Ito N; Sakai Y; Ohnishi S; Suekane H; Kurose H; Hiroshige T; Chikui K; Nishihara K; Nakiri M; Suekane S; Ogasawara S; Yano H; Igawa T
Curr Oncol; 2024 Mar; 31(4):1701-1712. PubMed ID: 38668032
[TBL] [Abstract][Full Text] [Related]
8. DNA Methylation Signatures Correlate with Response to Immune Checkpoint Inhibitors in Metastatic Melanoma.
Ressler JM; Tomasich E; Hatziioannou T; Ringl H; Heller G; Silmbrod R; Gottmann L; Starzer AM; Zila N; Tschandl P; Hoeller C; Preusser M; Berghoff AS
Target Oncol; 2024 Mar; 19(2):263-275. PubMed ID: 38401029
[TBL] [Abstract][Full Text] [Related]
9. Comparative Epigenetic Profiling Reveals Distinct Features of Mucosal Melanomas Associated with Immune Cell Infiltration and Their Clinical Implications.
Dai J; Jia J; Zhang F; Liu K; Xi Y; Yuan P; Mao L; Bai X; Wei X; Wang B; Li J; Xu Y; Liu T; Chang S; Shao Y; Guo J; Ying J; Si L
Cancer Res Commun; 2024 May; 4(5):1351-1362. PubMed ID: 38695555
[TBL] [Abstract][Full Text] [Related]
10. Targeting PD-L2-RGMb overcomes microbiome-related immunotherapy resistance.
Park JS; Gazzaniga FS; Wu M; Luthens AK; Gillis J; Zheng W; LaFleur MW; Johnson SB; Morad G; Park EM; Zhou Y; Watowich SS; Wargo JA; Freeman GJ; Kasper DL; Sharpe AH
Nature; 2023 May; 617(7960):377-385. PubMed ID: 37138075
[TBL] [Abstract][Full Text] [Related]
11. Circulating Cell-Free SHOX2 DNA Methylation Is a Predictive, Prognostic, and Monitoring Biomarker in Adjuvant and Palliative Anti-PD-1-Treated Melanoma.
Fietz S; Diekmann E; de Vos L; Zarbl R; Hunecke A; Glosch AK; Färber M; Sirokay J; Hoffmann F; Fröhlich A; Franzen A; Strieth S; Landsberg J; Dietrich D
Clin Chem; 2024 Mar; 70(3):516-527. PubMed ID: 38300881
[TBL] [Abstract][Full Text] [Related]
12. TNFSF4 (OX40L) expression and survival in locally advanced and metastatic melanoma.
Roszik J; Markovits E; Dobosz P; Layani A; Slabodnik-Kaner K; Baruch EN; Ben-Betzalel G; Grimm E; Berger R; Sidi Y; Schachter J; Shapira-Frommer R; Avni D; Markel G; Leibowitz-Amit R
Cancer Immunol Immunother; 2019 Sep; 68(9):1493-1500. PubMed ID: 31501955
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemistry assessment of tissue neutrophil-to-lymphocyte ratio predicts outcomes in melanoma patients treated with anti-programmed cell death 1 therapy.
Teixeira RJ; de Souza VG; Sorroche BP; Paes VG; Zambuzi-Roberto FA; Pereira CAD; Vazquez VL; Arantes LMRB
Melanoma Res; 2024 Jun; 34(3):234-240. PubMed ID: 38364053
[TBL] [Abstract][Full Text] [Related]
14. Polycomb repressor complex 2 suppresses interferon-responsive MHC-II expression in melanoma cells and is associated with anti-PD-1 resistance.
James JL; Taylor BC; Axelrod ML; Sun X; Guerin LN; Gonzalez-Ericsson PI; Wang Y; Sanchez V; Fahey CC; Sanders ME; Xu Y; Hodges E; Johnson DB; Balko JM
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38315170
[TBL] [Abstract][Full Text] [Related]
15. Quantitative analysis of CMTM6 expression in tumor microenvironment in metastatic melanoma and association with outcome on immunotherapy.
Martinez-Morilla S; Zugazagoitia J; Wong PF; Kluger HM; Rimm DL
Oncoimmunology; 2020 Dec; 10(1):1864909. PubMed ID: 33457084
[TBL] [Abstract][Full Text] [Related]
16. Silencing of interferon regulatory factor gene 6 in melanoma.
Nobeyama Y; Nakagawa H
PLoS One; 2017; 12(9):e0184444. PubMed ID: 28877249
[TBL] [Abstract][Full Text] [Related]
17. Pan-cancer analyses of bromodomain containing 9 as a novel therapeutic target reveals its diagnostic, prognostic potential and biological mechanism in human tumours.
Chen Y; Gao Z; Mohd-Ibrahim I; Yang H; Wu L; Fu Y; Deng Y
Clin Transl Med; 2024 Feb; 14(2):e1543. PubMed ID: 38303608
[TBL] [Abstract][Full Text] [Related]
18. TGF-β mRNA levels in circulating extracellular vesicles are associated with response to anti-PD1 treatment in metastatic melanoma.
Crucitta S; Cucchiara F; Marconcini R; Bulleri A; Manacorda S; Capuano A; Cioni D; Nuzzo A; de Jonge E; Mathjissen RHJ; Neri E; van Schaik RHN; Fogli S; Danesi R; Del Re M
Front Mol Biosci; 2024; 11():1288677. PubMed ID: 38633217
[No Abstract] [Full Text] [Related]
19. CD52 mRNA expression predicts prognosis and response to immune checkpoint blockade in melanoma.
de Vos-Hillebrand L; Fietz S; Hillebrand P; Kulcsár Z; Diop MY; Hollick S; Maas AP; Strieth S; Landsberg J; Dietrich D
Pigment Cell Melanoma Res; 2024 Mar; 37(2):309-315. PubMed ID: 37975535
[TBL] [Abstract][Full Text] [Related]
20. Impact of response patterns for patients with advanced acral melanoma treated with anti-programmed death-1 monotherapy.
Zhou L; Shao L; Gao S; Cui C; Chi Z; Sheng X; Tang B; Mao L; Lian B; Yan X; Wang X; Bai X; Li S; Guo J; Si L
Br J Dermatol; 2023 Jan; 188(1):112-121. PubMed ID: 36689499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
